- Center dedicated to research and development activities to advance Sarepta’s industry-leading, multi-platform pipeline
- The Center encompasses 85,000 square feet of space, tripling Sarepta’s footprint in
Ohio
The 85,000 square foot state-of-the-art facility expands Sarepta’s research and development capabilities and footprint, which includes sites in
“Advances in the science of genetic medicine are creating incredible opportunities to develop medicines with the potential to transform the lives of people with rare diseases. Sarepta’s
Among the guests joining the Sarepta team today for a dedication, ribbon-cutting ceremony and facility tours: The Honorable
“Sarepta has operated in
“Sarepta Therapeutics’ decision to expand in
About
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Forward-Looking Statements
This press release contains "forward-looking statements." Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements regarding potential opportunities in the rare disease space; the potential transformative benefits of medicines in the rare disease space; our plans to double the number of employees in
These forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Many of these risks and uncertainties are beyond our control. Known risk factors include, among others: we may not be able to execute on our business plans and goals, including meeting our expected or planned regulatory milestones and timelines, clinical development plans, and bringing our product candidates to market, due to a variety of reasons, many of which are outside of our control, including possible limitations on company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover our product candidates; the impact of the COVID-19 pandemic; and those risks identified under the heading “Risk Factors” in our most recent Annual Report on Form 10-K for the year ended
Any of the foregoing risks could materially and adversely affect the Company’s business, results of operations and the trading price of Sarepta’s common stock. For a detailed description of risks and uncertainties we face, we encourage you to review our
Source:
Investor Contact:
iestepan@sarepta.com
Media Contact:
tsorrentino@sarepta.com
Multimedia
- Sarepta’s
Genetic Therapies Center of Excellence –Building Exterior - Grand Opening Ceremony (
Oct 4, 2021 )
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/a2e78dd7-47fc-440c-bb7e-e8fb3abb992f
https://www.globenewswire.com/NewsRoom/AttachmentNg/e902e92d-0591-4dfd-b6f5-c1a82a9591e9
Sarepta’s Genetic Therapies Center of Excellence – Building Exterior
The new, state-of-the-art research facility encompasses 85,000 square feet and significantly expands Sarepta’s global research and development capabilities.
Grand Opening Ceremony (Oct 4, 2021 )
Sarepta’s Chief Scientific Officer Louise Rodino-Klapac and CEO Doug Ingram were joined by distinguished guests including The Honorable JON HUSTED , Lieutenant Governor, State of Ohio ; EDDIE PAULINE , President & CEO, BioOhio; JESSICA EVANS , Psy.D., Assistant Director, Speak Foundation ; PAT FURLONG , President & CEO, Parent Project Muscular Dystrophy; and representatives from state and local government.
2021 GlobeNewswire, Inc., source